Dupilumab in atopic dermatitis: predictors of treatment outcome and time to response.

I Dear Editor i , Recently, dupilumab, an anti-IL-4R antibody, has become available for the treatment of moderate-to-severe atopic dermatitis (AD).1-4 Baseline patient characteristics that can be used as predictors of response to dupilumab treatment in AD patients have not yet been identified. In conclusion, this study highlights that specific baseline patient characteristics may help to predict treatment outcomes and the time of a complete response to dupilumab in AD. [Extracted from the article]